Generic PediaPred Availability
PediaPred is a brand name of prednisolone, approved by the FDA in the following formulation(s):
PEDIAPRED (prednisolone sodium phosphate - solution; oral)
Has a generic version of PediaPred been approved?
Yes. The following products are equivalent to PediaPred:
prednisolone sodium phosphate solution; oral
-
Manufacturer: HI TECH PHARMA
Approval date: March 26, 2003
Strength(s): EQ 5MG BASE/5ML [AA] -
Manufacturer: PADDOCK LLC
Approval date: May 25, 2004
Strength(s): EQ 5MG BASE/5ML [AA] -
Manufacturer: WOCKHARDT
Approval date: June 28, 2002
Strength(s): EQ 5MG BASE/5ML [AA]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of PediaPred. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
There are no current U.S. patents associated with PediaPred.
See also...
- PediaPred liquid Consumer Information (Wolters Kluwer)
- Pediapred solution Consumer Information (Wolters Kluwer)
- Pediapred Consumer Information (Cerner Multum)
- Pediapred Advanced Consumer Information (Micromedex)
- Prednisolone Consumer Information (Wolters Kluwer)
- Prednisolone acetate suspension Consumer Information (Wolters Kluwer)
- Prednisolone sodium phosphate Consumer Information (Wolters Kluwer)
- Prednisolone sodium phosphate liquid Consumer Information (Wolters Kluwer)
- Prednisolone sodium phosphate solution Consumer Information (Wolters Kluwer)
- Prednisolone syrup Consumer Information (Wolters Kluwer)
- Prednisolone Consumer Information (Cerner Multum)
- Pms-Prednisolone Advanced Consumer Information (Micromedex)
- Prednisolone Advanced Consumer Information (Micromedex)
- Prednisolone AHFS DI Monographs (ASHP)
- Prednisolone Sodium Phosphate AHFS DI Monographs (ASHP)
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AA | Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved. |
